NAS
FTH

NWF Advisory Services’s Faeth Therapeutics FTH Stock Holding History

NWF Advisory Services’s Portfolio FTH Stock Details FTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-826
Closed -$6.51K – 438
2025
Q1 		$6.51K Hold
826
– – ﹤0.01% 362
2024
Q4 		$8.09K Buy
+826
New +$8.29K ﹤0.01% 281

Other funds holding FTH

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $3.65B AUM 41.88% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

NWF Advisory Services's FTH Position: Q2 2025 in Review

NWF Advisory Services sold out of Faeth Therapeutics (FTH) in Q2 2025, closing a stake of 826 shares — an estimated $6.51K sold.

NWF Advisory Services first reported a position in FTH in Q4 2024 and held it in 2 quarters. The position peaked at $8.09K in Q4 2024. 10 funds tracked by Wall St. Rank hold FTH as of Q2 2025.

  • NWF Advisory Services reported no remaining Faeth Therapeutics position as of Q2 2025 after selling out during the quarter.
  • NWF Advisory Services sold 826 Faeth Therapeutics shares in Q2 2025, an estimated $6.51K.
  • NWF Advisory Services first reported a position in Faeth Therapeutics in Q4 2024 and held it in 2 quarters.
  • NWF Advisory Services's Faeth Therapeutics position peaked at $8.09K in Q4 2024.
  • 10 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q2 2025.

Based on NWF Advisory Services's 13F filing for Q2 2025, filed 9 Sep 2025.